Myconostica Announces CE Marking of MycAssay Aspergillus For Serum

| Print |
Monday, 06 September 2010 10:00 (UTC + 2)

myconostica_logo_

Manchester, United Kingdom, September 6, 2010 / b3c newswire / - Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces the CE marking of its lead product MycAssay™ Aspergillus for detection of Aspergillus DNA in serum.


The CE marking is in addition to the existing CE marking for respiratory samples means, that MycAssay™Aspergillus is now CE marked for all major sample types.

 

MycAssay™ Aspergillus is a molecular diagnostic test for the detection of Aspergillus spp DNA. The kit is designed to be used by qualified laboratory professionals; the results provided by MycAssay™ Aspergillus aid physicians to make a diagnosis in patients suspected of having an infection caused by Aspergillus. It provides rapid and accurate results to physicians, enabling appropriate drug treatments to be administered thereby improving patient outcomes.

 

Dr. John Thornback, Myconostica’s Chief Business Officer, said:  “It is becoming increasingly recognised that Aspergillus DNA is present in serum and its measurement can be important in aiding the diagnosis of Aspergillus infections.  There are a number of different high risk patient groups for whom it is difficult to obtain respiratory samples.  The CE marking of MycAssay™ Aspergillus for serum now enables serum samples from these at risk patients to be tested using a fully validated assay.



About Myconostica Ltd. - www.myconostica.co.uk
Myconostica Ltd, a UK-based medical diagnostic company, specialises in rapid and highly specific tests for life-threatening fungal infections. Traditional methods of the detection of fungal infections are well documented as being relatively insensitive and slow.  Tests provided by Myconostica aim to allow healthcare professionals to rapidly identify patients infected thus enabling clinicians to prescribe appropriate drug therapy.

 

Myconostica is developing and commercialising a portfolio of real-time molecular diagnostic tests for life-threatening fungal infections. Over 10 million people are at risk of these infections each year in Europe and North America alone.

 

For further information please contact:

Myconostica Ltd
Heidi Wahlefeld-Moghimi
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
+44 (0)161 998 7239